Burden of eosinophilic granulomatosis with polyangiitis in Europe.

Background and aims

Real-world evidence characterising the burden of eosinophilic granulomatosis with polyangiitis (EGPA) in Europe is limited. The aim of this study was to characterise patients in a large European EGPA cohort.

Methods

This retrospective, non-interventional, longitudinal study (GSK ID: 214661) recruited cross-specialty physicians from France, Germany, Italy, Spain and the UK to conduct medical chart reviews for patients with a physician-confirmed diagnosis of EGPA. Patients were ≥12 years of age at diagnosis with ≥1 year of follow-up data from the first clinical visit with the physician (index date). Outcome measures collected from index date to end of follow-up included clinical manifestations and healthcare resource utilisation (HCRU).

Results

In total, 407 patient medical charts were reviewed by 204 physicians; median (interquartile range) duration of follow-up from index date was 2.2 (1.7-3.5) years. Most patients (73.5%) had asthma. Patients underwent multiple diagnostic assessments, and 74.9% received ≥3 different therapies between diagnosis and end of follow-up (98.8% oral corticosteroids, 63.9% immunosuppressive therapies, 45.5% biologics). During follow-up, 84.5% of patients experienced EGPA clinical manifestations; most were considered moderate or severe and commonly affected the lungs (55.8%; including lung infiltrates 25.8% and severe asthma 24.8%), ear, nose and throat (53.3%), and skin (41.8%). HCRU was substantial: 26.0% of patients made emergency department visits, 36.6% were hospitalised and 84.8% had outpatient visits.

Conclusions

These real-world data show that EGPA presents a substantial burden to patients and the healthcare system. Earlier and better differential diagnosis and appropriate treatment may help reduce incidence of clinical manifestations and HCRU.

Informations de copyright

Copyright ©The authors 2024.

Déclaration de conflit d'intérêts

Conflict of interest: R.W. Jakes, N. Kwon, J. Hwee, L. Baylis and R. Alfonso-Cristancho are employed by GSK, or were at the time of the study, and hold financial equities in GSK. Conflict of interest: L. Huynh, S. Du, A. Khanal and M. Sheng Duh are employees of Analysis Group, Inc., or were at the time of the study. Analysis Group, Inc. received research funds from GSK to conduct the study and have received research funds for previous studies from GSK, AbbVie, Apellis, AstraZeneca, Ayala Pharmaceuticals, Bayer, Blueprint Medicines, Humacyte, Janssen, Merck, Novartis, Pfizer, Sanofi and Takeda. Conflict of interest: B. Terrier reports consulting fees from AstraZeneca, Vifor, and GSK; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AstraZeneca, Vifor, GSK, and Boehringer Ingelheim and support for attending meetings and/or travel from Vifor and GSK.